On May 14, 2019, the Company entered into an Underwriting Agreement with Citigroup Global Markets Inc., Credit Agricole Securities (USA) Inc., MUFG
Securities Americas Inc. and Wells Fargo Securities, LLC, as representatives of the several underwriters listed therein (collectively, the Underwriters), for the issuance and sale by the Company of $750 million aggregate principal
amount of its 3.800% notes due 2029 (the Notes). The closing of the offering occurred on May 16, 2019.
The Notes were issued pursuant to
an indenture, dated as of November 21, 2017, between the Company and The Bank of New York Mellon, as trustee (the Indenture), as supplemented by the Second Supplemental Indenture, dated as of May 16, 2019 (the Second
Supplemental Indenture).
The Notes were issued in an underwritten public offering pursuant to the Companys Registration Statement on Form
S-3ASR
filed with the Securities and Exchange Commission on May 6, 2019 (Reg.
No. 333-231251)
(the Registration Statement) and related prospectus, dated
May 6, 2019, and prospectus supplement, dated May 14, 2019.
Interest on the Notes is payable semi-annually in arrears on June 1 and
December 1 of each year, commencing on December 1, 2019, and on the maturity date for the Notes. The Notes will mature on June 1, 2029. The Notes are the Companys direct unsecured and unsubordinated obligations and rank equally
with the Companys other unsecured and unsubordinated indebtedness from time to time outstanding. The Notes are structurally subordinated to all existing and future obligations at the Companys subsidiaries.
The foregoing description of the Notes and related agreements is qualified in its entirety by the terms of the Underwriting Agreement, the Indenture, and the
Second Supplemental Indenture (including the form of the Notes), which are filed as Exhibits 1.1 and 4.1 through 4.3, respectively, hereto and are incorporated herein by reference and incorporated by reference into the Registration Statement. An
opinion regarding the legality of the Notes is filed as Exhibit 5.1 hereto, and is incorporated by reference into the Registration Statement, and a consent relating to the incorporation of such opinion is incorporated by reference into the
Registration Statement and is filed as Exhibit 23.1 hereto by reference to its inclusion within Exhibit 5.1.